Bausch + Lomb Buys Blink Eye Drop From J&J for $106.5 Million
06 July 2023 - 9:53PM
Dow Jones News
By Ben Glickman
Bausch + Lomb said Thursday it had acquired the Blink eye drop
product line from Johnson & Johnson's Vision segment for $106.5
million, to be paid with cash on hand.
The deal follows another recent acquisition by the Canadian
eye-care company to expand its portfolio. The Wall Street Journal
reported that Bausch + Lomb is planning to buy Xiidra, a dry-eye
drug, from Novartis for $1.75 billion, with potential add-on
payments of up to $750 million.
Bausch + Lomb Chief Executive Brett Saunders, known for pursuing
mergers and acquisitions, returned to the company in March after
previously leading it from 2010 to 2013.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
July 06, 2023 07:38 ET (11:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Bausch and Lomb (TSX:BLCO)
Historical Stock Chart
From Apr 2024 to May 2024
Bausch and Lomb (TSX:BLCO)
Historical Stock Chart
From May 2023 to May 2024
